Touchlight

Touchlight is an innovation-driven leading CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution. As pioneers with an FDA Drug Master Filing already accepted in 2022, our enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and in vivo gene editing innovation. With multiple client products already in the clinic, our evidence-based, data-supported synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. Our company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, our team is inspired by breakthroughs in genome sequencing, recognizing the urgent need for innovative DNA production techniques to support the future of genetic therapies. To address these challenges, we developed our first novel synthetic DNA vector, dbDNA™, alongside a proprietary enzymatic manufacturing process. This groundbreaking approach enables the production of complex DNA sequences with remarkable speed, scale, and purity, surpassing the limitations of traditional pDNA production while transforming the economics of bringing these therapies to market more efficiently and sustainably. Touchlight’s commitment to innovation is continually fueling product improvements and new product development. As of early 2024, we have partnered with hundreds of biotech and top 10 pharmaceutical companies, producing synthetic DNA for use as both a starting material and an active pharmaceutical ingredient. By the end of this year, dbDNA™ will be one of multiple synthetic DNA products in our portfolio that will continue to pave the way for more accessible cell and gene therapies.